ArticleScientific reports2025

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy.

Tatsushi Kawada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.